相似文献
1
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma.
Cancer Cell. 2006 May;9(5):341-9. doi: 10.1016/j.ccr.2006.03.029.
2
Isoform specific inhibitors of PI3 kinase in glioma.
Cell Cycle. 2006 Oct;5(20):2301-5. doi: 10.4161/cc.5.20.3362. Epub 2006 Oct 16.
3
New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).
Curr Top Microbiol Immunol. 2010;347:241-62. doi: 10.1007/82_2010_64.
4
PTEN down regulates AP-1 and targets c-fos in human glioma cells via PI3-kinase/Akt pathway.
Mol Cell Biochem. 2007 Jun;300(1-2):77-87. doi: 10.1007/s11010-006-9371-8. Epub 2007 Jan 18.
5
Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia.
Cancer Res. 2009 Apr 15;69(8):3520-8. doi: 10.1158/0008-5472.CAN-08-4884. Epub 2009 Apr 7.
6
PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas.
J Neurooncol. 2005 Feb;71(3):215-22. doi: 10.1007/s11060-004-1718-y.
7
NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas.
Mol Cancer Ther. 2009 Aug;8(8):2204-10. doi: 10.1158/1535-7163.MCT-09-0160. Epub 2009 Aug 11.
8
The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growth-inhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo.
Cancer Res. 2006 Dec 1;66(23):11331-40. doi: 10.1158/0008-5472.CAN-06-1540.
9
FK228 augmented temozolomide sensitivity in human glioma cells by blocking PI3K/AKT/mTOR signal pathways.
Biomed Pharmacother. 2016 Dec;84:462-469. doi: 10.1016/j.biopha.2016.09.051. Epub 2016 Sep 28.
10
Dual inhibition of phosphatidylinositol 3-kinase/Akt and mammalian target of rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid fisetin.
Int J Cancer. 2012 Apr 1;130(7):1695-705. doi: 10.1002/ijc.26178. Epub 2011 Aug 26.
引用本文的文献
1
Ribosome Biogenesis and Function in Cancer: From Mechanisms to Therapy.
Cancers (Basel). 2025 Jul 31;17(15):2534. doi: 10.3390/cancers17152534.
2
PI3K/mTOR Signaling Pathway Dual Inhibition for the Management of Neuroinflammation: Novel Insights from In Vitro Models.
Biomolecules. 2025 May 7;15(5):677. doi: 10.3390/biom15050677.
3
pH-responsive bond as a linker for the release of chemical drugs from RNA-drug complexes in endosome or lysosome.
RNA Nanomed. 2024;1(1):91-108. doi: 10.59566/isrnn.2024.0101091.
4
HaloTag as a substrate-based macroautophagy reporter.
Proc Natl Acad Sci U S A. 2024 Aug 6;121(32):e2322500121. doi: 10.1073/pnas.2322500121. Epub 2024 Jul 29.
5
Advances in synthetic lethality modalities for glioblastoma multiforme.
Open Med (Wars). 2024 Jun 10;19(1):20240981. doi: 10.1515/med-2024-0981. eCollection 2024.
6
PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6 uterine leiomyosarcoma to PD-1 blockade.
Clin Transl Med. 2024 May;14(5):e1655. doi: 10.1002/ctm2.1655.
7
Shear stress induces autophagy in Schlemm's canal cells via primary cilia-mediated SMAD2/3 signaling pathway.
Autophagy Rep. 2023;2(1). doi: 10.1080/27694127.2023.2236519. Epub 2023 Jul 20.
8
Protein Kinase Inhibitors as a New Target for Immune System Modulation and Brain Cancer Management.
Int J Mol Sci. 2022 Dec 10;23(24):15693. doi: 10.3390/ijms232415693.
9
Initiation of muscle protein synthesis was unrelated to simultaneously upregulated local production of IGF-1 by amino acids in non-proliferating L6 muscle cells.
PLoS One. 2022 Jul 8;17(7):e0270927. doi: 10.1371/journal.pone.0270927. eCollection 2022.
10
Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment.
Front Pharmacol. 2022 May 9;13:875372. doi: 10.3389/fphar.2022.875372. eCollection 2022.
本文引用的文献
1
A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.
Cell. 2006 May 19;125(4):733-47. doi: 10.1016/j.cell.2006.03.035. Epub 2006 Apr 27.
2
TORgeting oncogene addiction for cancer therapy.
Cancer Cell. 2006 Feb;9(2):77-9. doi: 10.1016/j.ccr.2006.01.021.
3
Exploiting the PI3K/AKT pathway for cancer drug discovery.
Nat Rev Drug Discov. 2005 Dec;4(12):988-1004. doi: 10.1038/nrd1902.
4
Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase.
Proc Natl Acad Sci U S A. 2005 Oct 4;102(40):14238-43. doi: 10.1073/pnas.0506925102. Epub 2005 Sep 21.
5
The Akt-mTOR tango and its relevance to cancer.
Cancer Cell. 2005 Sep;8(3):179-83. doi: 10.1016/j.ccr.2005.08.008.
6
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.
Cancer Res. 2005 Aug 15;65(16):7052-8. doi: 10.1158/0008-5472.CAN-05-0917.
7
hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase.
J Biol Chem. 2005 Sep 23;280(38):33076-82. doi: 10.1074/jbc.M507201200. Epub 2005 Jul 27.
8
Tyrosine kinases as targets for cancer therapy.
N Engl J Med. 2005 Jul 14;353(2):172-87. doi: 10.1056/NEJMra044389.
9
CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium.
Cancer. 2005 Sep 1;104(5):1045-8. doi: 10.1002/cncr.21265.
10
An expanding role for mTOR in cancer.
Trends Mol Med. 2005 Aug;11(8):353-61. doi: 10.1016/j.molmed.2005.06.007.
Zotero 插件